Which obesity medication is contraindicated in a patient on monoamine oxidase inhibitors?

Which obesity medication is contraindicated in a patient on monoamine oxidase inhibitors?

• A. Liraglutide
• B. Bupropion/naltrexone
• C. Lorcaserin
• D. Phentermine/topiramate ER

Answer: (D)

When you’re on an MAO inhibitor, the body’s levels of monoamines such as norepinephrine are already elevated because breakdown is blocked. Adding a medication that further boosts monoamines or stimulates the sympathetic nervous system can trigger dangerous hypertension and related cardiovascular events. Phentermine/topiramate ER combines a stimulant that increases norepinephrine release with another weight-loss agent, and this pushes the sympathetic response over the edge in someone taking an MAOI. That’s why this combination is contraindicated. Other obesity medications don’t share that direct risk with MAO inhibitors. Liraglutide acts as a GLP-1 receptor agonist and works through appetite and insulin pathways rather than monoamines, so there isn’t a monoamine-driven interaction to worry about. Lorcaserin targets serotonin pathways but isn’t known for a specific MAOI contraindication. Bupropion/naltrexone has dopaminergic/adrenergic effects, so caution is prudent, but the strongest, explicit contraindication with MAO inhibitors is the stimulant-containing option.

When you’re on an MAO inhibitor, the body’s levels of monoamines such as norepinephrine are already elevated because breakdown is blocked. Adding a medication that further boosts monoamines or stimulates the sympathetic nervous system can trigger dangerous hypertension and related cardiovascular events. Phentermine/topiramate ER combines a stimulant that increases norepinephrine release with another weight-loss agent, and this pushes the sympathetic response over the edge in someone taking an MAOI. That’s why this combination is contraindicated.

Other obesity medications don’t share that direct risk with MAO inhibitors. Liraglutide acts as a GLP-1 receptor agonist and works through appetite and insulin pathways rather than monoamines, so there isn’t a monoamine-driven interaction to worry about. Lorcaserin targets serotonin pathways but isn’t known for a specific MAOI contraindication. Bupropion/naltrexone has dopaminergic/adrenergic effects, so caution is prudent, but the strongest, explicit contraindication with MAO inhibitors is the stimulant-containing option.